PRODUCTLIFE GROUP ACQUIRES COMMERCIAL EYES, EXPANDING ITS FOOTPRINT IN THE APAC REGION
Posted: 1 February 2024 ProductLife Group (PLG), the specialised global provider of regulatory, scientific, vigilance, quality and digital transformation consulting services for the life sciences industries, announces the acquisition of Commercial Eyes, Australia’s leading pharmaceutical and medical device…
Cumming Global Centre for Pandemic Therapeutics awards AU$17 million in grant funding
Posted: 1 February 2024 Developing antiviral therapeutics for respiratory infections using gene editing and mRNA technologies and creating a suite of precision microbiome-based biotherapeutics are just two groundbreaking projects being funded by the Cumming Global Centre for Pandemic…
Placenta cells may lower blood pressure
Posted: 1 February 2024 The research, led by La Trobe Senior Lecturer in Physiology and Pharmacology, Dr Michael De Silva, and published in Scientific Reports, has advanced La Trobe’s recent studies into using placenta cells for stroke recovery, has passed…
The secret life of CD4+ T cells: from helpers to melanoma fighters
Posted: 1 February 2024 Researchers have revealed unprecedented insights into CD4+ T cells, a type of immune cell, which show promise for immunotherapies against melanoma, the most severe form of skin cancer. In the study led by the…
80-year mystery solved: Mosquitoes spread flesh-eating Buruli ulcer
Posted: 1 February 2024 In a major breakthrough, researchers led by University of Melbourne’s Professor Tim Stinear, Director of the WHO Collaborating Centre for Mycobacterium ulcerans at the Peter Doherty Institute for Infection and Immunity (Doherty Institute), have solved the 80-year…
Viraleze shows antiviral efficacy in COVID-19 patients
Posted: 29 January 2024 Starpharma today announces the results of the post-market[2] clinical study of Viraleze™ nasal spray in participants with COVID-19, demonstrating that Viraleze™ reduced SARS-CoV-2 viral load in the nose, increased the rate of virus clearance from…
Made In Victoria: A Groundbreaking Peanut Allergy Therapy
Posted: 29 January 2024 The Allan Labor Government’s investment into a local biotechnology firm will bring peanut allergy sufferers around the world one step closer to an innovative new treatment that could save lives. Minister for Economic Growth…
Research overturns thinking into potential Parkinson’s disease target
Posted: 29 January 2024 A new study has found a molecule hailed as a potential drug candidate for Parkinson’s disease is no longer an effective therapeutic option. The WEHI-led research has debunked over 10 years of research that suggested a…
Study pinpoints breast cancer ‘cells-of-origin’ in high-risk women
Posted: 29 January 2024 Scientists have pinpointed likely ‘cells-of-origin’, the source cells that can grow into breast cancer, in women carrying a faulty BRCA2 gene who are at high risk of developing the disease. The WEHI-led study also showed…
New Cellular Lab To Back Victorian Blood Cancer Research
Posted: 29 January 2024 The Allan Labor Government is celebrating the opening of a new cellular laboratory at St Vincent’s Hospital Melbourne, which deliver more local research into blood cancers than ever before. Acting Minister for Health Ingrid…
Discovery of drug candidate to potentially tackle ER-positive breast cancer
Posted: 29 January 2024 An international team of researchers, led by Pfizer in collaboration with Monash University and the Australian-based Cancer Therapeutics Cooperative Research Centre, have discovered a pre-clinical drug candidate demonstrating anti-tumour activity in Estrogen Receptor (ER)…
4DMedical partners with Philips to expand US Defence commercialisation
Posted: 25 January 2024 ASX-listed imaging technology developer 4DMedical Limited has signed a teaming agreement with Koninklijke Philips, a leading global healthcare company, to commercialise 4D Medical’s XV Technology within the US Department of Veterans Affairs. The partnership marks a…
